Progression-Free Survival (PFS) Benefit Demonstrated and Quality of Life (QoL) Maintained across Age and Frailty Subgroups with the Oral Proteasome Inhibitor (PI) Ixazomib Vs Placebo As Post-Induction Maintenance Therapy in Non-Transplant Newly Diagnosed Multiple Myeloma (NDMM) Patients (Pts): Analysis of the TOURMALINE-MM4 Phase 3 Trial

Sara Bringhen,Luděk Pour,Reuben Benjamin,Sebastian Grosicki,Chang-Ki Min,Danielle Leao Cordeiro De Farias,Alexander Vorog,Richard J Labotka,Bingxia Wang,Dasha Cherepanov,Lauren E Cain,Sudhakar Manne,S Vincent Rajkumar,Meletios A Dimopoulos

doi:10.1182/blood-2020-136293

Progression-Free Survival (PFS) Benefit Demonstrated and Quality of Life (QoL) Maintained across Age and Frailty Subgroups with the Oral Proteasome Inhibitor (PI) Ixazomib Vs Placebo As Post-Induction Maintenance Therapy in Non-Transplant Newly Diagnosed Multiple Myeloma (NDMM) Patients (Pts): Analysis of the TOURMALINE-MM4 Phase 3 Trial

Sara Bringhen, Luděk Pour + Show 12 more

Open Access

https://doi.org/10.1182/blood-2020-136293

Copy DOI

Journal: Blood	Publication Date: Nov 5, 2020
Citations: 6

Affiliation: Azienda Ospedaliera Citta' della Salute e della Scienza di Torino, University Hospital Brno, King's College Hospital NHS Foundation Trust, Medical University of Silesia, Seoul St. Mary's Hospital, Beneficência Portuguesa de São Paulo, Universidade Federal de Goiás, Takeda (United States), Millennium Engineering and Integration (United States), Mayo Clinic, National and Kapodistrian University of Athens

#Progression-Free Survival Benefit #Millennium Pharmaceuticals + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

Progression-Free Survival (PFS) Benefit Demonstrated and Quality of Life (QoL) Maintained across Age and Frailty Subgroups with the Oral Proteasome Inhibitor (PI) Ixazomib Vs Placebo As Post-Induction Maintenance Therapy in Non-Transplant Newly Diagnosed Multiple Myeloma (NDMM) Patients (Pts): Analysis of the TOURMALINE-MM4 Phase 3 Trial

Full Text